Table 2.
Impact of the clinical–demographic, nutritional and genetic factors on the SGA scoring
| Factor | A | B and C | p OR [95% CI] | A and B | C | p OR [95% CI] |
|---|---|---|---|---|---|---|
| SGA | ||||||
| Gender | ||||||
| Male | 7 (13.7%) | 44 (86.3%) |
0.705 0.716 [0.127–4.03] |
32 (62.6%) | 19 (37.4%) |
0.614 1.404 [0.377–5.231] |
| Female | 2 (18.2%) | 9 (81.8%) | 6 (54.5%) | 5 (45.5%) | ||
| Age (years) | ||||||
| ≥ 63 | 7 (21.9%) | 25 (78.1%) |
0.107 3.92 [0.744–20.65] |
20 (62.5%) | 12 (37.5%) |
0.840 1.111 [0.40–3.09] |
| < 63 | 2 (6.7%) | 28 (93.3%) | 18 (60%) | 12 (40%) | ||
| Performance status (PS) | ||||||
| < 1 | 9 (16.4%) | 46 (83.6%) |
0.456 3.065 [0.161–58.35] |
36 (65.5%) | 19 (34.5%) |
0.08 4.737 [0.839–26.76] |
| > 1 | 0 | 7 | 2 (28.6%) | 5 (71.4%) | ||
| Histopathological diagnosis | ||||||
| Squamous-cell carcinoma | 8 (14%) | 49 (86%) |
0.718 0.653 [0.064–6.614] |
33 (57.9%) | 24 (42.1%) |
0.165 0.124 [0.007–2.355] |
| Others | 1 (20%) | 4 (80%) | 5 | 0 | ||
| Disease stage | ||||||
| I and III | 2 (14.3%) | 12 (85.7%) |
0.978 0.976 [0.179–5.333] |
10 (71.4%) | 4 (28.6%) |
0.380 1.786 [0.490–6.512] |
| IV | 7 (14.6%) | 41 (85.4%) | 28 (58.3%) | 20 (41.7%) | ||
| Tumor location | ||||||
| Upper throat | 3 (17.6%) | 14 (82.4%) |
0.668 1.393 [0.306–6.333] |
13 (76.5%) | 4 (23.5%) |
0.139 2.600 [0.733–9.217] |
| Lower throat | 6 (13.3%) | 39 (86.7%) | 25 (55.6%) | 20 (44.4%) | ||
| Larynx | 5 (14.7%) | 29 (85.3%) |
0.963 1.035 [0.250–4.287] |
19 (55.9%) | 15 (44.1%) |
0.337 0.600 [0.212–1.702] |
| Others | 4 (14.3%) | 24 (85.7%) | 19 (67.9%) | 9 (32.1%) | ||
| Alcohol consumption | ||||||
| Yes | 4 (14.3%) | 24 (85.7%) |
0.963 0.967 [0.233–4.001] |
14 (50%) | 14 (50%) |
0.101 0.417 [0.147–1.185] |
| No | 5 (14.7%) | 29 (85.3%) | 24 (70.6%) | 10 (29.4%) | ||
| Smoking status | ||||||
| Smoker | 8 (15.4%) | 44 (84.6%) |
0.661 1.636 [0.182–14.75] |
31 (59.6%) | 21 (40.4%) |
0.539 0.633 [0.147–2.729] |
| Non-smoker | 1 (10%) | 9 (90%) | 7 (70%) | 3 (30%) | ||
| Concurrent CTH | ||||||
| Yes | 2 (8.3%) | 22 (91.7%) |
0.284 0.403 [0.076–2.125] |
13 (54.3%) | 11 (45.7%) |
0.362 0.615 [0.216–1.749] |
| No | 7 (18.4%) | 31 (81.6%) | 25 (65.8%) | 13 (34.2%) | ||
| BMI (I) All patients | ||||||
| < 24.9 | 4 (10%) | 37 (90%) |
0.148 0.346 [0.082–1.460] |
21 (51.2%) | 20 (48.8%) |
0.028 4.048 [2.160–14.12] |
| > 25 | 5 (23.8%) | 16 (76.2%) | 17 (70.8%) | 4 (29.2%) | ||
| < 18.5 | 1 (10%) | 9 (90%) |
0.661 0.611 [0.068–5.510] |
4 (40%) | 6 (60%) |
0.141 0.353 [0.088–1.414] |
| > 18.5 | 8 (15.4%) | 44 (84.6%) | 34 (65.4%) | 18 (34.6%) | ||
|
Weight loss (I vs VII) All patients |
||||||
| < 5% | 2 (6.7%) | 28 (93.3%) |
0.107 0.255 [0.048–1.344] |
23 (76.7%) | 7 (23.3%) |
0.019 3.724 [1.246–11.13] |
| > 5% | 7 (21.9%) | 25 (78.1%) | 15 (46.9%) | 17 (53.1%) | ||
| < 10% | 4 (10%) | 36 (90%) |
0.137 0.333 [0.078–1.416] |
22 (55%) | 18 (45%) |
0.175 0.458 [0.149–1.414] |
| > 10% | 5 (25%) | 15 (75%) | 16 (72.7%) | 6 (27.3%) | ||
| Genotype distribution of TNF-α −1031T/C | ||||||
| CC | 0 | 6 |
0.527 0.385 [0.020–7.420] |
1 (11.1%) | 5 (88.9%) |
0.044 9.737 [1.061–89.40] |
| CT and TT | 9 (16.1%) | 47 (83.9%) | 37 (66.1%) | 19 (33.9%) | ||
| TT | 9 (24.3%) | 28 (75.7%) |
0.055 17.0 [0.941–306.99] |
31 (83.8%) | 6 (16.2%) |
0.0001 13.29 [3.862–45.70] |
| CT and CC | 0 | 25 | 7 (28%) | 18 (72%) |